IXI Raises $36.5 Million In Series A Funding Led By Plural And Amazon Alexa Fund

Finland-based eyewear startup IXI, co-founded by CEO Niko Eiden and chief algorithm officer Ville Miettinen, has raised $36.5 million in funding to develop smart prescription glasses that automatically adjust focus using eye-tracking and liquid crystal lens technology. The round was led by Plural with backing from the Amazon Alexa Fund, Tesi, byFounders, Heartcore, Eurazeo, and others. Drawing on its team’s experience from Nokia and Varjo, IXI aims to simplify vision correction by replacing bifocals and varifocals with seamless, autofocus eyewear — marking its first public step toward commercializing the technology. INVESTORS: Plural, Amazon Alexa Fund, Tesi, byFounders, Heartcore, Eurazeo, FOV Ventures & Tiny Supercomputer ROUND: Series A AMOUNT: $36,500,000 HQ: #Espoo #Finland #VentureCapital #IXI #AmazonAlexaFundTesi #byFounders #Heartcore #Eurazeo #FOVVentures #TinySupercomputer #NikoEiden #TradedVC

More Deals

View All

Colossal Biosciences In Talks For Funding Round Targeting $23 Billion ValuationColossal Biosciences, the de-extinction biotech startup known for its efforts to recreate the woolly mammoth and other extinct species, is reportedly in talks to raise new funding at a valuation of roughly $23 billion–$24 billion, according to Axios. The potential raise would mark a significant jump for the five-year-old company, with investors valuing not only its genetic-engineering programs but also its broader genomics, reproductive technology, conservation, and intellectual property platform. Colossal has begun generating revenue through conservation technology sales and technology spinouts, including Astromech, an AI-driven predictive modeling company, and Form Bio, a computational biology platform, expanding its value beyond de-extinction efforts. FOUNDERS: Ben Lamm & George Church TARGET VALUATION: $23,000,000,000 HQ: Dallas, Texas #VentureCapital #ColossalBiosciences #BenLamm #GeorgeChurch #TradedVC